Persivia Powers the Next Era of Digital Health with Strategic $107 Million Investment and AI Innovation Patent
MARLBOROUGH, Mass., May 7, 2025 /PRNewswire/ - Persivia, the company behind one of the healthcare industry's most advanced digital health platforms, today announced two major developments—a $107M investment from Aldrich Capital Partners and the issuance of U.S. Patent No. 12,254,975 B2 for its Health Data Processing System. This dual milestone signals a new era for healthcare, as Persivia prepares to scale its proven AI-first platform and transform how care is delivered, measured, and managed across the continuum.
The newly granted patent protects the core AI capabilities behind CareSpace®, Persivia's modular digital health platform. Unlike typical platforms that merely surface data, CareSpace® uses Soliton®, a now-patented AI engine to ingest, analyze, prioritize, and deliver actionable insights in real time. This allows care teams to respond to the most urgent needs, manage complex patient populations, and streamline workflows—all from a unified interface.
Aldrich's investment—completed at the end of February—provides the financial firepower to expand quickly and invest deeply in platform innovation, client success, and go-to-market execution.
It also puts Persivia in a position few companies can claim: deeply funded, clinically validated, and now legally protected as the innovator of a patented AI-driven platform.
'This isn't just a win for Persivia, it is a great day for US healthcare as a whole,' said Dr. Mansoor Khan, CEO of Persivia. 'With the industry-leading platform, new capital and a newly issued patent, we're ready to deliver on a vision that's been 20 years in the making—solving healthcare's toughest challenges with an AI core that is now patented, proven, and deployed at scale.'
At the heart of this transformation is CareSpace®, a digital health platform designed to help organizations thrive while transitioning from fee-for-service to value-based care. It supports a wide range of use cases – from data, care, quality and population health management to analytics, virtual care, risk adjustment and many more. Built on a modular architecture with the Soliton® AI engine at its core, CareSpace® gives healthcare organizations the flexibility to deploy exactly what they need, when they need it—without the overhead of point solution sprawl.
'Most healthcare AI solutions today are point solutions that bolt on to existing platforms,' said Dr. Fauzia Khan, CMO of Persivia. 'The CareSpace® platform is built around the Soliton® AI engine which resides at the heart of the system. This vision of AI at the heart of all data flows, analytics and workflows forms the basis for our patent, which was applied for in early 2020, long before AI was the buzzword it is now.'
As the healthcare industry faces mounting pressure to do more with less, Persivia is delivering a platform that combines speed, intelligence, and interoperability—driving better outcomes, lowering costs, and reducing burnout. With the issuance of this patent, the company is sending a clear message: the era of intelligent, AI-driven care has arrived, and Persivia is leading it.
To learn more about Persivia and the patented AI system powering CareSpace®, visit www.persivia.com
About Persivia
Persivia delivers an AI-powered platform that helps healthcare organizations work smarter. By unifying clinical, claims, social, and operational data into one intelligent system, Persivia turns complex data into real-time insights that drive decisions, streamline workflows, and improve performance across the board.
Whether it's powering value-based care, optimizing risk, improving quality, or managing cost and utilization. Learn more at www.persivia.com . The platform gives payers and providers the tools to move faster, act earlier, and operate more efficiently.
Headquartered in Marlborough, MA, Persivia supports 200+ hospitals and 12,000+ clinicians nationwide.
View original content to download multimedia: https://www.prnewswire.com/news-releases/persivia-powers-the-next-era-of-digital-health-with-strategic-107-million-investment-and-ai-innovation-patent-302448023.html
SOURCE Persivia Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
APsystems Unveils Full-Scope AI-Driven Solar & Storage Solutions at SNEC 2025
SHANGHAI, June 12, 2025 /PRNewswire/ -- APsystems made a strong impression at the 18th SNEC PV Power & Energy Storage Expo, held at the National Exhibition and Convention Center in Shanghai. With more than 15 years of disruptive technological innovation, the company introduced its latest advancements in solar and storage technologies, highlighting new products and showcasing the impact of AI integration on energy management. Leading with Innovation: New Product LaunchesAPsystems is introducing the QS2, a brand new single-phase quad microinverter with an impressive 2200W output and support for four high-power PV modules via independent MPPT channels. Designed for safety and efficiency, its module-level architecture keeps DC voltage below 60V during operation, effectively minimizing high-voltage risks. The upgraded Zigbee module enhances communication speed and stability, while the QS2's compatibility with other APsystems single-phase models like the DS3 and QS1 makes system design more flexible. Also introduced was the AHS series Solar Battery Hybrid Controller, designed for off-grid and backup power scenarios. Supporting 12V/24V/48V lead-acid and lithium batteries, the flagship AHS-6.3 delivers a 6300VA pure sine wave output with 99.9% MPPT efficiency and seamless 5ms UPS switching. With IP43 cooling and real-time app monitoring, it's built for reliability in both home and telecom applications. Versatile Solar + Storage Solutions for Every NeedAPsystems highlighted its complete lineup of distributed energy solutions across micro, residential, and commercial applications. The EZ1/EZHI series empower DIY users with microgrid capabilities and energy independence. For residential settings, 20A microinverters and ELS/ELT storage options provide flexible options. In the C&I space, the QT2 three-phase microinverters and Ocean series storage systems are designed for cost efficiency and scalable performance. Smarter Energy with AI IntegrationA major focus this year was APsystems' AI-driven enhancements. The new BESS AI model uses deep learning to forecast energy generation and consumption based on historical data and local energy prices. This enables automatic, personalized charge/discharge schedules for balcony and residential storage systems—delivering smarter, more efficient energy use. APsystems also unveiled APbot, a smart support assistant built on advanced AI architecture using private LLM deployment and RAG technology. Designed to improve customer interaction, APbot delivers fast, accurate responses using semantic search and knowledge-based reasoning, all while being easily adaptable for global compliance needs. The AP Designer tool also received an AI boost. Now featuring image recognition, real-time simulation, and 3D modeling, it streamlines PV design by analyzing rooftops, trees, and shading. With online design capabilities and automatic report generation, it simplifies everything from planning to budget forecasting. Thank you to everyone who visited our booth at SNEC 2025. We appreciate your interest and look forward to connecting again next time! View original content to download multimedia: SOURCE Altenergy Power System Inc.
Yahoo
42 minutes ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
TPIsoftware Drives Vietnam's Industry 4.0 by Accelerating Nam Cau Kien Industrial Park Green Transformation with Newly-Launched ESG Platform 'Shinec Digital Green Economy'
TAIPEI, June 12, 2025 /PRNewswire/ -- Today, Shinec Joint Stock Company, the developer of Nam Cau Kien Industrial Park (IP), officially launched its ESG application platform, "Shinec Digital Green Economy," marking a significant milestone on its journey toward sustainable development. This event not only represents a major step in the comprehensive digitalization of the IP's operational management but also affirms Nam Cau Kien's pioneering role in creating an eco-industrial park, advancing towards Net-Zero targets, and unlocking the potential for carbon credit generation. TPIsoftware supports the park sustainability initiative with the "Shinec Digital Green Economy" platform, a comprehensive solution powered by the company's GreenSwift (smart carbon management platform) and ElectriSwift (smart energy management system), with GGI Technology serving as the ESG consultant. The platform functions as an intelligent IP management system focused on digitalizing environmental management, emissions control, and security. Through this platform, the solution provides a holistic management system, from real-time carbon emissions data collection and analysis of emission and energy consumption hotspots to recommending and monitoring improvement strategies. The superiority of "Shinec Digital Green Economy" is demonstrated through its diverse integrated features: Greenhouse Gas (GHG) Emissions Management (powered by GreenSwift): Streamlines carbon data collection, analysis and reporting, ensuring auditing and inventory efficiency through an integrated platform, aligning the inventory process with international standards such as ISO 14064-1. Smart Energy Management (powered by ElectriSwift): Monitors and detects energy inefficiencies based on acquired power usage patterns, providing insights into energy consumption with real-time alerting for optimized energy-saving strategies. Wastewater Monitoring and Treatment: Tracks water quality indicators (pH, TSS, COD, BOD, Ammonia) before and after treatment and calculates the corresponding GHG emissions. Intelligent Security Monitoring: Integrates AIoT into the camera system to issue instant security alerts for events such as crowd detection, fence climbing, accidents, and fires. Visual Reporting: Provides an intuitive dashboard on both mobile and web platforms, allowing management to access reports anytime, anywhere, facilitating timely and effective decision-making. In the face of intense pressure from global climate change, Carbon Management Systems (CMS) are emerging as a new global trend, aligning with international accords such as the Paris Agreement (2015), Net Zero 2050, and COP26/COP28. These frameworks compel businesses to reduce carbon emissions. Regulations like the EU's Carbon Border Adjustment Mechanism (CBAM) impose carbon tariffs on imported goods, forcing exporting enterprises to measure and manage their carbon footprint. Globally, CMS is becoming mandatory for listed companies (under IFRS S2, CSRD), while carbon pricing (taxes, ETS) is being strengthened in developing nations. Japan and South Korea are leading with carbon pricing policies (carbon tax, ETS), with corporations like Toyota and Samsung already implementing CMS to achieve their Net Zero 2050 goals. Indonesia and Malaysia are focusing on CMS in the oil and gas and agricultural sectors. The Indian government has promoted its Carbon Credit Trading Scheme (CCTS) since 2023. China is at the forefront of implementing robust policies to support its businesses in transitioning towards carbon neutrality by 2060 and is a pioneer in IP carbon management, investing in carbon offset projects across ASEAN and Africa. Vietnam is committed to achieving net zero by 2050 and will pilot a carbon credit exchange, including mechanisms for trading and offsetting credits, while preparing to officially launch a carbon credit trading floor connected to regional and international markets by 2028. CMS adoption in Vietnam is expected to grow, driven by FDI and export requirements. The government will support SMEs through tax incentives and training. Vietnamese businesses are encouraged to invest in CMS early to mitigate carbon tax risks and enhance global competitiveness. Investing in this green and digital solution not only helps Nam Cau Kien IP optimize operations and reduce costs through efficient energy and resource use but is also a strategic move to enhance its brand reputation through environmental responsibility. This positions the IP to achieve ISO certifications for energy management (ISO 50001) and carbon neutrality (ISO 14068). Furthermore, the next phase of the project is expected to digitize green spaces—which account for 31% of the entire IP, including trees, shrubs, lawns, and water features—and renewable energy sources. This will create a solid foundation for calculating carbon sequestration and tapping into the future carbon credit market for the developer. Nam Cau Kien Industrial Park, under Shinec's strategic investment, marks the group's commitment to creating an eco-industrial park model toward achieving carbon neutrality. The collective efforts of Shinec's pioneering vision, GGI Technology's expert consultancy, and TPIsoftware's strengths in implementing impactful sustainability initiatives are poised for broader deployment across Shinec's eco-industrial parks and other industrial parks in Vietnam. The launch of "Shinec Digital Green Economy" not only elevates the stature of Shinec and Nam Cau Kien IP within the Vietnamese and regional industrial park landscape but also builds significant credibility for its implementation partners, GGI Technology and TPIsoftware. It affirms their capacity to consult on and deliver advanced green technology solutions, contributing significantly to Vietnam's national sustainable development goals. View original content to download multimedia: SOURCE TPIsoftware Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
